ICU Medical Stock (NASDAQ:ICUI), Trade Ideas

ICU Medical

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.

News

Price Target

Small Cap

Markets

Analyst Ratings

Trading Ideas

APLS

AXON

ICUI

STRL

TARS

TREE

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

ICU Medical To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday

Earnings

Movers

ICU Medical, Inc. (NASDAQ: ICUI) shares traded lower on Tuesday following mixed third-quarter results. 

ICU Medical Stock Plunged Today - Here&#39;s Why

Penny Stocks

Intraday Update

ADTN

ALPN

ALTO

AMRC

ATSG

AUGX

AURA

CHRS

CLOV

CNHI

DCGO

DDOG

EVCM

EVER

FGEN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

JWEL

LIFW

MGNX

MYGN

NINE

OLPX

OMIC

OPRT

OSCR

PLNT

PRAA

PXMD

RMCO

ROVR

SAGE

SANM

SGRY

SNOW

SNTI

TASK

TCMD

TDUP

THAR

TMDX

TRIP

TWKS

VMEO

VTYX

WLDS

WWAC

Gainers


	PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.


Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

ICU Medical Inc

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Oppenheimer boosted the price target for Tarsus Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tars#NASDAQ">TARS</a>) from $55 to $59. Oppenheimer analyst Francois Brisebois reiterated an Outperform rating. Tarsus Pharmaceuticals shares gained 18.3% to close at $39.22 on Tuesday. <a href="https://www.benzinga.com/quote/TARS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush increased the price target for Apellis Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apls#NASDAQ">APLS</a>) from $60 to $67. Wedbush analyst Laura Chico maintained a Neutral rating. Apellis Pharmaceuticals shares fell 3.3% to close at $69.35 on Tuesday. <a href="https://www.benzinga.com/quote/APLS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham increased Axon Enterprise, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axon#NASDAQ">AXON</a>) price target from $240 to $315. Needham analyst Joshua Reilly maintained a Buy rating. Axon Enterprise shares rose 0.1% to close at $271.82 on Tuesday. <a href="https://www.benzinga.com/quote/AXON/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho slashed the price target for Essex Property Trust, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ess#NYSE">ESS</a>) from $255 to $250. Mizuho analyst Vikram Malhorta upgraded the stock from Neutral to Buy. Essex Property Trust shares gained 0.9% to close at $227.73 on Tuesday. <a href="https://www.benzinga.com/quote/ESS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James lowered Integral Ad Science Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ias#NASDAQ">IAS</a>) price target from $20 to $16. Raymond James analyst Andrew Marok downgraded the stock from Strong Buy to Outperform. Integral Ad Science shares gained 1.4% to close at $17.10 on Tuesday. <a href="https://www.benzinga.com/quote/IAS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson boosted the price target for Sterling Infrastructure, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/strl#NASDAQ">STRL</a>) from $86 to $115. DA Davidson analyst Brent Thielman downgraded the stock from Buy to Neutral. Sterling Infrastructure shares climbed 18.1% to close at $106.22 on Tuesday. <a href="https://www.benzinga.com/quote/STRL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham boosted LendingTree, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tree#NASDAQ">TREE</a>) price target from $17 to $40. Needham analyst Mayank Tandon maintained a Buy rating. LendingTree shares fell 4.8% to close at $32.62 on Tuesday. <a href="https://www.benzinga.com/quote/TREE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc boosted ICU Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icui#NASDAQ">ICUI</a>) price target from $134 to $136. Keybanc analyst Brett Fishbin maintained an Overweight rating. ICU Medical shares climbed 1.2% to close at $106.81 on Tuesday. <a href="https://www.benzinga.com/quote/ICUI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays raised Ecolab Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ecl#NYSE">ECL</a>) price target from $225 to $260. Barclays analyst Manav Patnaik upgraded the stock from Equal-Weight to Overweight. Ecolab shares gained 0.8% to close at $222.09 on Tuesday. <a href="https://www.benzinga.com/quote/ECL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group increased Abercrombie &amp; Fitch Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/anf#NYSE">ANF</a>) price target from $105 to $140. Telsey Advisory Group maintained an Outperform rating. Abercrombie &amp; Fitch shares fell 0.3% to close at $125.78 on Tuesday. <a href="https://www.benzinga.com/quote/ANF/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/02/37360001/these-3-energy-stocks-with-over-5-dividend-yields-are-recommended-by-wall-streets-most-a"> These 3 Energy Stocks With Over 5% Dividend Yields Are Recommended By Wall Street&#39;s Most Accurate Analysts </a>

Keybanc analyst Brett Fishbin maintains ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) with a Overweight and raises the price target from $134 to $136.

Keybanc Maintains Overweight on ICU Medical, Raises Price Target to $136

For Fiscal Year 2024 the Company estimates GAAP net loss to be in the range of&nbsp;$(88)&nbsp;to&nbsp;$(71)&nbsp;and GAAP diluted loss per share estimated to be in the range of&nbsp;$(3.57)&nbsp;to&nbsp;$(2.87). The Company expects adjusted EBITDA to be in the range of&nbsp;$330 million&nbsp;to&nbsp;$370 million.

Guidance

ICU Medical Expects FY24 Adjusted EPS Of $4.40-$5.10, Est $5.18

ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) reported its Q4 earnings results on Tuesday, February 27, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
ICU Medical beat estimated earnings by 32.0%, reporting an EPS of $1.57 versus an estimate of $1.19.
Revenue was up $9.84 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.19 which was followed by a 17.0% drop in the share price the next day.
Here's a look at ICU Medical's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.38</td>
<td>1.55</td>
<td>1.43</td>
<td>1.56</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.57</td>
<td>1.88</td>
<td>1.74</td>
<td>1.60</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>565.75M</td>
<td>562.90M</td>
<td>565.30M</td>
<td>578.77M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>553.31M</td>
<td>549.31M</td>
<td>568.65M</td>
<td>578.01M</td>
</tr>
</tbody>
</table>

To track all earnings releases for ICU Medical <a href="https://www.benzinga.com/quote/ICUI/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: ICU Medical Q4 Earnings

ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) reported quarterly earnings of $1.57 per share which beat the analyst consensus estimate of $1.19 by 31.93 percent. The company reported quarterly sales of $587.86 million which beat the analyst consensus estimate of $563.02 million by 4.41 percent. This is a 1.70 percent increase over sales of $578.01 million the same period last year.

Earnings Beats

ICU Medical Q4 2023 Adj EPS $1.57 Beats $1.19 Estimate, Sales $587.86M Beat $563.02M Estimate

ACAD

ACHC

AESI

AHCO

AIRS

ALEC

ALHC

AMBA

AMBC

ARKO

ARQT

ARRY

ATEC

BCSF

BECN

BGFV

BMBL

BWXT

BYND

CAVA

CBRL

CIVI

CLDT

CLNE

CLVT

CMLS

COMP

CPNG

CRDO

CYTK

EBAY

EHTH

ESPR

FARO

FLYW

FOUR

FSLR

FULC

GDOT

GLPI

GMRE

GSX Techedu Inc. American Depositary Shares

GOTU

GPOR

HRZN

HSIC

HURN

ICCC

ICFI

IMAX

IMXI

INGN

INSE

IPAR

JAMF

KIND

KURA

KVYO

LAZR

LGND

LGVN

Earnings Scheduled For February 27, 2024

<h3>Gainers</h3>
<ul>
<li>Janux Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>) shares moved upwards by 64.2% to $24.8 during Monday's after-market session. The company's market cap stands at $1.1 billion. </li>
<li>ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) stock increased by 59.8% to $168.75. The market value of their outstanding shares is at $4.0 billion. </li>
<li>Galera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTX#NASDAQ">GRTX</a>) stock increased by 27.6% to $0.24. The market value of their outstanding shares is at $13.3 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares increased by 15.9% to $11.88. The company's market cap stands at $2.5 billion. The company's, Q4 earnings came out today. </li>
<li>TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) shares increased by 15.84% to $90.06. The company's market cap stands at $2.9 billion. As per the news, the Q4 earnings report came out today. </li>
<li>BiomX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) shares rose 13.89% to $0.24. The market value of their outstanding shares is at $11.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) stock decreased by 20.5% to $0.34 during Monday's after-market session. The market value of their outstanding shares is at $28.9 million. </li>
<li>Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) shares decreased by 8.89% to $16.0. The company's market cap stands at $659.3 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock declined by 7.08% to $0.45. The company's market cap stands at $4.1 million. </li>
<li>ThermoGenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) shares fell 7.06% to $0.79. The market value of their outstanding shares is at $2.4 million. </li>
<li>Assure Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) shares declined by 5.01% to $0.35. The company's market cap stands at $2.3 million. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) shares decreased by 4.99% to $0.28. The company's market cap stands at $7.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSGM

ELVN

GRTX

IONM

JANX

KZIA

NRXP

PHGE

THMO

12 Health Care Stocks Moving In Monday's After-Market Session

ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-02-27. Here's what investors need to know before the announcement.
Analysts estimate that ICU Medical will report an earnings per share (EPS) of $1.19. 
ICU Medical bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.19, which was followed by a 17.31% drop in the share price the next day.
Here's a look at ICU Medical's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.38</td>
<td>1.55</td>
<td>1.43</td>
<td>1.56</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.57</td>
<td>1.88</td>
<td>1.74</td>
<td>1.60</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-17.0%</td>
<td>-17.0%</td>
<td>14.000000000000002%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1708966950_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of ICU Medical were trading at $103.59 as of February 23. Over the last 52-week period, shares are down 38.73%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/ICUI/earnings">To track all earnings releases for ICU Medical visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ICU Medical's Earnings: A Preview

Keybanc analyst Brett Fishbin initiates coverage on ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) with a Overweight rating and announces Price Target of $134.

Initiation

Keybanc Initiates Coverage On ICU Medical with Overweight Rating, Announces Price Target of $134

CL King analyst Kristen Stewart initiates coverage on ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) with a Buy rating and announces Price Target of $110.

CL King Initiates Coverage On ICU Medical with Buy Rating, Announces Price Target of $110

ICU Medical, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icui#NASDAQ">ICUI</a>) shares traded lower on Tuesday following mixed third-quarter results.&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/news/23/11/35654105/why-sanmina-shares-are-trading-lower-by-around-15-here-are-other-stocks-moving-in-tuesdays-mid-day-s" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Here&#39;s what happened</a>.
What To Know:&nbsp;ICU Medical reported after the close of the market on Monday. Quarterly earnings of $1.57 per share beat the analyst consensus estimate of $1.38, a 10.29% decrease over earnings of $1.75 per share from the same period last year.
The company reported quarterly sales of $553.31 million, which lagged the analyst consensus estimate of $565.75 million.&nbsp;
The figure represents a 7.45% decrease over sales of $597.86 million in the same period last year.
Shares of the company fell Tuesday on unusually high volume in response to the results. According to data from Benzinga Pro, the stock experienced an above-average trading volume of 1.34 million shares compared to its average volume of 214,124.
Related Link:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/news/23/11/35657272/whats-going-on-with-cigna-stock-today" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">What&#39;s Going On With Cigna Stock Today?</a>
ICUI Price Action:&nbsp;Shares of ICUI plunged 17.3% on Tuesday, according to&nbsp;<a class="editor-rtfLink" href="http://pro.benzinga" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Benzinga Pro</a>.
Image by&nbsp;<a class="editor-rtfLink" href="https://pixabay.com/users/triggermouse-19438543/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=5835701" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Triggermouse</a>&nbsp;from&nbsp;<a class="editor-rtfLink" href="https://pixabay.com//?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=5835701" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Pixabay</a>

ICU Medical Stock Plunged Today - Here's Why

<h3>Gainers</h3>
<ul>
<li>PaxMedica, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pxmd#NASDAQ">PXMD</a>) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.</li>
<li>Senti Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snti#NASDAQ">SNTI</a>) gained 83% to $0.5298 after the company reported a new strategic collaboration with Celest Therapeutics for the clinical development of SENTI-301A in China. Senti is eligible to receive up to $156 million in milestones and royalties.</li>
<li>Tharimmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/thar#NASDAQ">THAR</a>) shares climbed 57.8% to $0.2488 as the company disclosed the execution of an exclusive worldwide licensing agreement with Avior Inc. d/b/a Avior Bio, LLC to develop, market and commercialize a clinical-stage asset, AV104.</li>
<li>TransMedics Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) shares gained 56.7% to $63.03 after the company reported better-than-expected third-quarter sales results and issued strong FY23 revenue guidance.</li>
<li>Singular Genomics Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omic#NASDAQ">OMIC</a>) rose 39.1% to $0.5350.</li>
<li>Olaplex Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/olpx#NASDAQ">OLPX</a>) gained 39% to $1.92 following strong quarterly results.</li>
<li>Datadog, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ddog#NASDAQ">DDOG</a>) climbed 28.6% to $102.28 after the company reported better-than-expected third-quarter results and issued strong guidance.</li>
<li>Augmedix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/augx#NASDAQ">AUGX</a>) shares rose 24% to $5.64 following strong third-quarter results.</li>
<li>Rover Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rovr#NASDAQ">ROVR</a>) gained 23.7% to $7.99 following upbeat results. The company&rsquo;s board also approved extension of share repurchase program with additional $100 million.</li>
<li>MacroGenics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgnx#NASDAQ">MGNX</a>) rose 20.6% to $6.57 after posting a profit for the third quarter.</li>
<li>Jowell Global Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jwel#NASDAQ">JWEL</a>) climbed 18% to $1.96.</li>
<li>Triumph Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tgi#NYSE">TGI</a>) rose 17.6% to $9.30 following strong quarterly results.</li>
<li>Alteryx, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ayx#NYSE">AYX</a>) shares jumped 17.3% to $35.74 after the company reported better-than-expected third-quarter financial results.</li>
<li>Unisys Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uis#NYSE">UIS</a>) shares jumped 16.7% to $3.3780 after the company posted upbeat third-quarter results and raised FY23 revenue growth forecast.</li>
<li>Thoughtworks Holding, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/twks#NASDAQ">TWKS</a>) rose 16.2% to $4.2050 after the company posted upbeat third-quarter results.</li>
<li>TaskUs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/task#NASDAQ">TASK</a>) gained 16% to $11.90 after the company reported better-than-expected third-quarter financial results and issued FY23 revenue guidance above estimates.</li>
<li>Myriad Genetics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mygn#NASDAQ">MYGN</a>) rose 15.8% to $18.92 after the company posted upbeat third-quarter results.</li>
<li>Planet Fitness, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/plnt#NYSE">PLNT</a>) climbed 15.8% to $63.92 after the company reported better-than-expected third-quarter financial results and raised FY23 revenue growth guidance.</li>
<li>EverQuote, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ever#NASDAQ">EVER</a>) gained 15.8% to $8.62 following strong sales.</li>
<li>Oscar Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/oscr#NYSE">OSCR</a>) climbed 14.3% to $6.53 following strong results.</li>
<li>Hims &amp; Hers Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hims#NYSE">HIMS</a>) rose 13.9% to $7.16 after the company reported better-than-expected third-quarter sales results, raised FY23 guidance above estimates and announced a $50 million share repurchase program.</li>
<li>Surgery Partners, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgry#NASDAQ">SGRY</a>) rose 13.2% to $28.08 following upbeat results.</li>
<li>Vimeo, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vmeo#NASDAQ">VMEO</a>) gained 13.2% to $3.7950 following upbeat results.</li>
<li>MongoDB, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdb#NASDAQ">MDB</a>) climbed 12.7% to $374.62.</li>
<li>PRA Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/praa#NASDAQ">PRAA</a>) climbed 11.3% to $16.12 following better-than-expected results.</li>
<li>Snowflake Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/snow#NYSE">SNOW</a>) rose 10.9% to $159.93 in sympathy with Datadog, which reported better-than-expected Q3 results and issued strong guidance.</li>
<li>DocGo Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dcgo#NASDAQ">DCGO</a>) gained 10.2% to $6.39 following strong sales.</li>
<li>Wearable Devices Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wlds#NASDAQ">WLDS</a>) surged 9.7% to $0.8006.</li>
<li>GSE Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gvp#NASDAQ">GVP</a>) rose 9.6% to $3.5961. GSE Solutions was recently awarded a $4.2 million contract from a large utility for nuclear power plant engineering work.</li>
<li>FibroGen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fgen#NASDAQ">FGEN</a>) gained 8.4% to $0.6062 following upbeat results.</li>
<li>Tripadvisor, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trip#NASDAQ">TRIP</a>) shares rose 4.8% to $16.89 after the company reported better-than-expected third-quarter financial results.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ventyx Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtyx#NASDAQ">VTYX</a>) shares fell 80.8% to $2.71 after the company announced efficacy results from the Phase 2 trial of VTX958 in plaque psoriasis did not meet the internal target to support further development of VTX958 in psoriasis.</li>
<li>Alto Ingredients, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alto#NASDAQ">ALTO</a>) fell 58.1% to $2.0594 after the company reported mixed third-quarter financial results.</li>
<li>Worldwide Webb Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wwac#NASDAQ">WWAC</a>) fell 51% to $3.56.</li>
<li>Oportun Financial Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/oprt#NASDAQ">OPRT</a>) fell 47% to $3.08 after reporting a loss for the third quarter.</li>
<li>Royalty Management Holding Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rmco#NASDAQ">RMCO</a>) dipped 41.6% to $5.80.</li>
<li>Aura Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aura#NASDAQ">AURA</a>) fell 33% to $7.37. Aura Biosciences priced its public offering of 11 million common shares at $9 per share.</li>
<li>ThredUp Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tdup#NASDAQ">TDUP</a>) fell 30.5% to $2.3901 following weak results.</li>
<li>ADTRAN Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adtn#NASDAQ">ADTN</a>) shares fell 28% to $5.28 following a wider-than-expected quarterly loss.</li>
<li>Olo Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/olo#NYSE">OLO</a>) fell 27% to $4.2650 following third-quarter results.</li>
<li>Ameresco, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amrc#NASDAQ">AMRC</a>) shares declined 27% to $19.42 following downbeat third-quarter results.</li>
<li>Air Transport Services Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atsg#NASDAQ">ATSG</a>) dropped 24.4% to $15.29. Air Transport Services reported weaker-than-expected results for its third quarter. The company also named Joe Hete, current Chairman of the Board and its former longtime CEO, as its CEO, effective immediately.</li>
<li>MSP Recovery, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lifw#NASDAQ">LIFW</a>) shares fell 24.2% to $7.32 after jumping 252% on Monday.</li>
<li>Coherus BioSciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chrs#NASDAQ">CHRS</a>) shares fell 23.2% to $2.72 after the company reported mixed third-quarter financial results.</li>
<li>Clover Health Investments, Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clov#NASDAQ">CLOV</a>) shares fell 20.1% to $0.8966 following weak quarterly sales.</li>
<li>Nine Energy Service, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nine#NYSE">NINE</a>) fell 19.4% to $2.7631 following downbeat sales.</li>
<li>Tactile Systems Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcmd#NASDAQ">TCMD</a>) fell 17.2% to $10.46 following quarterly results.</li>
<li>Sterling Infrastructure, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/strl#NASDAQ">STRL</a>) declined 16.3% to $62.42 following weak sales.</li>
<li>ICU Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icui#NASDAQ">ICUI</a>) fell 16.3% to $85.34 following downbeat sales.</li>
<li>EverCommerce Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evcm#NASDAQ">EVCM</a>) dipped 15% to $8.16 following weak sales.</li>
<li>Sanmina Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sanm#NASDAQ">SANM</a>) shares fell 14.5% to $45.15 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Alpine Immune Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alpn#NASDAQ">ALPN</a>) fell 11.4% to $12.49. Alpine Immune Sciences priced its $150 million public offering of 8.8 million common shares at $12.50 per share.</li>
<li>CNH Industrial N.V. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cnhi#NYSE">CNHI</a>) fell 8.6% to $10.36 after the company reported mixed third-quarter financial results and issued guidance.</li>
<li>Sage Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sage#NASDAQ">SAGE</a>) declined 7.4% to $19.09 following third-quarter results.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/23/11/35645492/ethereum-falls-below-this-key-level-neo-becomes-top-loser"> Ethereum Falls Below This Key Level; Neo Becomes Top Loser</a>

Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

WIIM

ICU Medical shares are trading lower following mixed Q3 results.

ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) reported quarterly earnings of $1.57 per share which beat the analyst consensus estimate of $1.38 by 13.77 percent. This is a 10.29 percent decrease over earnings of $1.75 per share from the same period last year. The company reported quarterly sales of $553.31 million which missed the analyst consensus estimate of $565.75 million by 2.20 percent. This is a 7.45 percent decrease over sales of $597.86 million the same period last year.

ICU Medical Q3 Adj EPS $1.57 Beats $1.38 Estimate, Sales $553.31M Miss $565.75M Estimate

The beginning of the week brought mixed performance for stocks on Wall Street, with the major indices trading close to the flatline during midday trading in New York following strong performance in the previous week.
The S&amp;P 500 index is in the midst of its fifth consecutive day of gains, while the Nasdaq 100 has already logged six consecutive days of positive returns. 
Monday&#8217;s rise in Treasury yields is presenting some challenges to further advances in the stock market. Defensive sectors like utilities, health care and staples outperformed cyclicals and tech. 
Federal Reserve Governor Lisa D. Cook delivered a speech at Duke University expressing the expectation that current policy measures are sufficiently restrictive to bring inflation back to the target rate of 2%.
Cues From Monday&#8217;s Trading:
The S&amp;P 500 was flat, while both the Nasdaq 100 and the Dow Jones Industrial Average were marginally higher by 0.1%. 
Small caps showcased a robust 1.2% drop, after a strong week of gains. 
 US Index Performance In Week Ended Nov. 3
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index </td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>+0.13%</td>
<td>15,123.28</td>
</tr>
<tr>
<td>S&amp;P 500 Index</td>
<td>+0.03%</td>
<td>4,360.18</td>
</tr>
<tr>
<td>Dow Industrials</td>
<td>+0.12%</td>
<td>34,102.32</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.18%</td>
<td>1,739.88</td>
</tr>
</tbody>
</table>
</figure>
Analyst Color: 
LPL Financial Chief Technical Strategist Adam Turnquist has taken the market&#8217;s comeback with a pinch of salt. The analyst noted that Thursday's 1.9% rally, powered by above-average volume and broad-based buying, pushed the index back above its closely watched 200-day moving average at 4,248. 
&#8220;While we view this as a step in the right direction, a close above 4,400 would be required for the index to reverse its emerging downtrend,&#8221; Turnquist said. &#8220;Furthermore, market breadth has been underwhelming amid the latest bounce, as less than half of the stocks within the S&amp;P 500 are trading above their 200-dma,&#8221; he added.
The analyst said more technical evidence is needed to affirm the lows of this correction have been set. Among the dynamics the analyst is watching for are:
<ul>
<li>the S&amp;P 500 to reverse its emerging downtrend with a close above 4,400.</li>
<li>breadth to expand with at least half of the index constituents getting back above their 200-DMA.</li>
<li>for 10-year yields to reverse their current uptrend with a move below 4.35%.</li>
</ul>
Monday Trading In Major US Equity ETFs
<ul>
<li>The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was 0.1% higher to $435.03.</li>
<li>The SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.1% to $340.90. </li>
<li>The Invesco QQQ Trust&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) was 0.2% higher to $368.55, according to <a href="https://benzinga.grsm.io/register174">Benzinga Pro data.</a></li>
</ul>
Looking at S&amp;P 500 sector ETFs:
<ul>
<li>The Real Estate&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) was the laggard, down 1.7%.</li>
<li>The Health Care&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) rose the most, up 0.6%. </li>
</ul>
See Also: <a href="https://www.benzinga.com/money/best-futures-to-trade">Best Futures To Trade</a>
Stocks In Focus:
Apple, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) rose about 1.2%, outperforming the other &#8220;Magnificent 7&#8221; stocks. 
Berkshire Hathaway Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) fell 1.8% despite its quarterly report showing a more than<a href="https://www.benzinga.com/markets/equities/23/11/35614060/warren-buffett-led-berkshire-hathways-ginormous-157b-cash-pile-is-nearing-levels-held-by-one-of-"> 41% increase in operating profit.</a>
BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) rose 4.8% following third-quarter results. 
DISH Network Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DISH#NASDAQ">DISH</a>) tumbled 22% after missing revenue estimates.
TreeHouse Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THS#NYSE">THS</a>) fell 10% following a revenue miss. 
Those reporting after the market close are Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), Sanmina Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANM#NASDAQ">SANM</a>), Goodyear Tire &amp; Rubber Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GT#NASDAQ">GT</a>), ADTRAN Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTN#NASDAQ">ADTN</a>), Unisys Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UIS#NYSE">UIS</a>), Tripadvisor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#NASDAQ">TRIP</a>), RingCentral, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>), OPKO Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>), NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>), Matterport, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTTR#NASDAQ">MTTR</a>), ICU Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) and Diamondback Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>). 
Commodities, Bonds, Other Global Equity Markets:
Crude oil rose 1.5%, with a barrel of WTI-grade crude trading at $81. The United States Oil Fund&nbsp;ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>) was 1.4% higher to $75.87.&nbsp;&nbsp;
Treasury yields were slightly higher,&nbsp;with the 10-year yield up by 7 basis points to 4.65% and the two-year yield up by 6&nbsp;basis points to 4.91%.&nbsp;The iShares 20+ Year Treasury Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NYSE">TLT</a>) was 0.9% lower for the day.&nbsp;
The dollar held steady, with the U.S. dollar index, which is tracked by the&nbsp;Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) flat. The EUR/USD pair, which is tracked by the Invesco CurrecyShares Euro Currency Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXE#NYSE">FXE</a>),&nbsp;was also flat at 1.0735.
European equity indices had a negative session. The SPDR DJ Euro STOXX 50 ETF&nbsp;&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FEZ#NYSE">FEZ</a>) fell 0.4%.&nbsp;
Gold edged 0.4% down&nbsp;to $1,983/oz, while silver fell 0.4% to $23.11. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) was 0.3% lower to $34,934.
Staff writer Piero Cingari updated this report midday Monday.&nbsp;
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/11/35613268/long-term-rates-to-drop-below-2-cathie-wood-says-would-love-the-fed-to-pay-attentio">Long-Term Rates To Drop Below 2%? Cathie Wood Says &#8216;Would Love The Fed To Pay Attention&#8217; To This Chart</a>
Photo via Shutterstock.

Equities

Broad U.S. Equity ETFs

Futures

Economics

Federal Reserve

Pre-Market Outlook

ETFs

$BTC

AAPL

BNTX

SPDR Dow Jones Industrial Average ETF Trust

DISH

FANG

MTTR

NXPI

iShares Trust Barclays 20+ Year Treasury Bond Fund

TSLA

PowerShares DB US Dollar Index Bullish Fund

VRTX

XLRE

Stocks Fight To Extend Winning Streak, Treasury Yields Rise: What's Driving Markets Monday?